Anavex Life Sciences Corp (AVXL)

[nidan7500]

McM wrote:

Many positives relational to clinical participants and clinical success for Trial targets..

The fact that no effective treatment for these CNS disease has been developed till now is actually a positive for A2-73 trials. The bar could not be any lower or more scientifically specific. Any/all positive results will be major CNS news. The new evaluation protocols will verify by objective evidence that A2-73 has produced (some) specific result. Dr.M. and staff have identified Bio/patient specific markers. This method of testing is far superior to decades of trials based on unproven causal association of Amyloid plaques to AD as an example.

The body of knowledge supporting CNS cellular homeostasis role in other CNS indications is robust and consistently w/o contradiction. As AUS continuing A2-73 trial results have shown low/no-residual patient risks and considering the complexity-risk of alternative treatments or not treating relational CNS diseases then cross prescription seems a logical option. Agree completely. IMO, by the time we get there this choice will be more obvious.